Next Article in Journal
Treatment of Refractory Congenital Pseudoarthrosis of Tibia with Contralateral Vascularized Fibular Bone Graft and Anatomic Distal Tibial Locking Plate: A Case Series and Literature Review
Next Article in Special Issue
Intra- and Juxta-Articular Osteoid Osteoma Mimicking Arthritis: Case Series and Literature Review
Previous Article in Journal
Genome-Wide Sequencing Modalities for Children with Unexplained Global Developmental Delay and Intellectual Disabilities—A Narrative Review
Previous Article in Special Issue
Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Children
Volume 10
Issue 3
10.3390/children10030502
children-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Chronic Nonbacterial Osteomyelitis and Inflammatory Bowel Disease: A Literature Review-Based Cohort

by
Stefania Costi
1,
Sabino Germinario
2,
Marco Pandolfi
2,
Maria Rosa Pellico
2,
Andrea Amati
2,
Maurizio Gattinara
1,
Cecilia Beatrice Chighizola
1,3,
Roberto Caporali
1,3,4 and
Achille Marino
1,*
1
Unit of Pediatric Rheumatology, ASST G. Pini-CTO, 20122 Milan, Italy
2
University of Milan, 20122 Milan, Italy
3
Department of Clinical Sciences and Community Health, Research Center for Pediatric and Adult Rheumatic Diseases (RECAP.RD), University of Milan, 20122 Milan, Italy
4
Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
Children 2023, 10(3), 502; https://doi.org/10.3390/children10030502
Submission received: 6 February 2023 / Revised: 27 February 2023 / Accepted: 1 March 2023 / Published: 3 March 2023
(This article belongs to the Special Issue State of the Art and Recent Advances in Pediatric Rheumatology)
Review Reports Versions Notes

Abstract

:
Background: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder that mainly involves children and adolescents. The association with other inflammatory disorders, such as inflammatory bowel disease (IBD), psoriasis, and arthritis, has been reported in the literature. In particular, the relationship between bone and intestinal inflammation is still poorly understood. For this purpose, our review aims to describe the cases reported in the literature concerning this association and to compare them with data from our single-center cohort of patients. Methods: We conducted a literature review of published cases of CNO associated with IBD. Eligible articles were identified through a Medline search in the PubMed database until December 2022. We retrospectively reviewed medical records of patients with CNO referred to G. Pini Hospital and compared them with the literature-review-based cohort. Results: Fifty-seven patients with a defined diagnosis of CNO and associated IBD were described in the literature (female 55%). The median age of onset of the disease (CNO or IBD) was 11 years. In 32/53 (60%), a diagnosis of Crohn’s disease (CD) was made, while 18 (34%) patients were classified as suffering from ulcerative colitis (UC) and 3 (6%) from undifferentiated IBD. The diagnosis of CNO preceded the diagnosis of IBD in 59% of cases; while in 24%, IBD anticipated CNO; and in 17%, the two conditions appeared simultaneously. The median time between the two events was 24 months. In our Italian cohort (n = 23 patients), no diagnosis of IBD was made. No significant differences were found when comparing clinical and demographical characteristics of the Italian vs. review-based cohort, except for a significant involvement of rachis in the Italian group. Conclusions: The correlation between autoinflammatory bone disease and intestinal inflammation should be further investigated. It is essential to promote awareness among pediatric rheumatologists and gastroenterologists about this possible association to facilitate the diagnosis and better optimize treatment.

1. Introduction

1.1. Chronic Nonbacterial Osteomyelitis: From Pathogenesis to Clinical Aspects

Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory disease of bone primarily affecting children and adolescents [1,2]. CNO includes various forms of bone inflammation, from mild and self-limiting conditions to chronic and severe multifocal diseases such as chronic recurrent multifocal osteomyelitis (CRMO).
CNO pathogenesis is largely unknown; however, an aberrant regulation of the innate immune system leading to cytokines disproportion toward a pro-inflammatory state (high level of IL-1, IL-6, and TNF-α and low level of IL-10) seems to promote the recurrence of bone inflammation [3]. In particular, it has been demonstrated that a fixed expression of pro-inflammatory cytokines and chemokines, promoted by the activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome [4], regulates osteoclast differentiation and activation through interactions between the receptor activator of nuclear factor-κB (RANK) on osteoclast precursor cells and its ligand (RANKL) [5,6]. NLRP3 is a central component of the innate immune system and, through caspase-1 activation, promotes the conversion to the active form of IL-1β. In support of this argument, an increased expression of NLRP3 inflammasome and IL-1β mRNA in peripheral blood mononuclear cells from CNO/CRMO patients has been described [3,7]. Indeed, Hofmann et al. reported reduced IL-10 and IL-19 expression contributing to NLRP3 inflammasome activation [3].
The majority of CNO patients do not show a clear genetic background, although, susceptible loci have been identified [8], suggesting a possible role of genetic factors in the pathogenesis of CNO/CRMO. There is evidence of family clusters of CNO/CRMO, and it has been shown that almost 50% of people diagnosed with CNO also have a personal or family history of other autoimmune or inflammatory diseases [9,10,11,12,13]. Genetic factors’ importance is also supported by the strong similarities between the sporadic form of CNO/CRMO and the monogenic ones. The most known monogenic forms of CNO/CRMO are Majeed Syndrome and Interleukin-1 Receptor Antagonist Deficiency Syndrome (DIRA). Both conditions are classified as autoinflammatory diseases, and belong to the group of ‘inflammasomopathies’, in which different mutations in genes encoding for inflammasome components or inflammasome regulator proteins lead to a pathological increase in IL-1β levels [14,15]. It is inherited in an autosomal recessive pattern. The syndrome is characterized by an early onset of sterile bone inflammation, dyserythropoietic anemia, and neutrophilic dermatosis. Disease onset is within 2 years of age and is usually associated with fever attacks, growth disturbances, and joint contractures. Some Majeed patients do not show skin manifestations. The efficacy of IL-1 blocking agents has indirectly confirmed the pathogenesis of Majeed syndrome [16,17]. DIRA results from a loss of-function mutations in IL1RN, causing a decrease in IL-1 receptor antagonist (IL-1RA) which promotes pro-inflammatory IL-1 signaling. Patients with DIRA show both skin and bone involvement along with systemic inflammation.
Indeed, it is characterized by multifocal sterile osteitis, periostitis, and pustulosis. Pustular lesions appear within the first months of life, while osteitis and periostitis occur later. Bone lesions show neutrophilic infiltration at biopsies. Widening of the anterior rib ends and periostitis of long bones are classically described in these patients. The exogenous IL-1 receptor antagonist, anakinra, is able to neutralize both IL-1α and IL-1β and is successfully employed in DIRA patients [18,19]. Deficiency of the interleukin (IL)-36 receptor antagonist (DITRA) is a recently described autosomal recessive autoinflammatory syndrome characterized clinically by recurrent episodes of generalized pustular psoriasis [20]. Cherubism is another rare monogenic autoinflammatory bone disease due to heterozygous mutations of SH3 binding protein 2 (SH3BP2) gene with variable penetrance and phenotypic manifestation within the same family. SH3BP2 plays a key role in osteoclast activation fostering bone resorption [21]. These patients show osteolytic lesions of mandibles very early in life; the following fibrotic tissue deposition and bone remodeling give the typical aspect of puffy cheeks to patients with cherubism. Cherubism treatment is based on case reports in which adalimumab and bisphosphonates have both been used. Cox et al. described a South Asian child, born to consanguineous parents, with CRMO and psoriasis carrying the homozygous mutation of the FBLIM1 gene [22]. The FBLIM1 gene encodes for Filamin-binding LIM protein 1 (FBLP1) or migfilin; this protein plays a key role in bone remodeling. FBLP1 regulates cytoskeleton activity; it binds adhesion proteins and filamin-containing actin filaments of cell-extracellular matrix (ECM) and participates in integrin activation. Mice deficient in FBLP1 show severe osteopenia due to increased osteoclast activation fostered by RANKL overexpression [23]. The FBLIM1 role in sterile bone inflammation is confirmed by a mouse model (Pstpip2-deficient) with chronic multifocal osteomyelitis that showed levels of FBLIM1 gene expression downregulated up to 20-fold compared to healthy mice [22]. After this proband, Cox et al., found another subject harboring a compound heterozygosis of FBLIM1 gene among 96 CRMO patients screened. More recently, an Italian group found a high frequency (22%) of rare variants of FBLIM1 in a multicentric cohort of patients with CNO. These data support the role of FBLIM1 in the pathogenesis of CNO [24].
CNO patients typically have a disease-onset age of around 10 years, with girls more frequently affected (female/male ratio of approximately 2:1) [9,11,25,26,27]. Although CNO has been considered to be quite rare, recent observations documented an increased incidence in tertiary centers [10,28]. CNO is probably underestimated due to diagnostic difficulties and low awareness among clinicians. Indeed, CNO is characterized by an insidious onset and variable clinical manifestations that may mimic infections or malignancies, and investigations (laboratory features and imaging) are non-specific [29]. The most common symptom at onset is insidious bone pain, and physical examinations may show tenderness to the affected site with or without local swelling [29], even though asymptomatic bone inflammation sites are frequently detected through imaging. Constitutional symptoms (low-grade fever, slight malaise, and fatigue) occur in less than 5% of patients [9,30]. Nocturnal bone pain may be present in some patients and can be misinterpreted as growing pains [13]. Bone lesions are usually multifocal and symmetric; long bones are frequently involved. Conventional radiography can identify osteolytic lesions with sclerosis (typical of an advanced stage of disease), but it is less useful at disease onset. On the other hand, magnetic resonance imaging (MRI), with short tau inversion recovery (STIR) sequences, is a more sensitive technique that can detect early bone lesions [31]. In this setting, whole-body MRI may help discriminate between mono or multifocal disease and is extremely useful in disease follow-up. Nowadays, CNO/CRMO remains a diagnosis of exclusion, and bone biopsies may allow for the clinician to rule out other diseases, such as tumors or infective osteomyelitis. The most common histological findings from CNO patients include dense infiltrates of immune cells, belonging both to the innate and adaptive immune systems, osteolysis, and fibrosis [32].

1.2. Inflammatory Bowel Diseases in Children: From Pathogenesis to Clinical Aspects

Inflammatory bowel diseases (IBDs) are a group of diseases characterized by immune activation and inflammation of the gastrointestinal tract. IBDs include Crohn’s disease (CD), ulcerative colitis (UC), and undifferentiated IBD (u-IBD) [33]. The pathogenesis of the disease is not yet clearly understood, but genetic factors, environmental insults, and dysbiosis seem to cooperate to determine the disease [34]. In spite of different phenotypes, approximately 30% of IBD-related genes are shared between CD and UC, suggesting common pathogenetic pathways; indeed, more than 50% of IBD susceptibility loci have also been related to other inflammatory/autoimmune diseases [34]. NOD2, C13orf31, and LRRK2 genes are associated both with susceptibility to CD and Mycobacterium leprae infection. Interestingly, NOD2 mutation has been shown to contribute to the dysfunction in the mucosal barrier integrity in CD. This has further led to an intense investigation into the impact of the gut microbiome dysbiosis in IBD.
In patients with a very early onset of IBD (before the age of 6), genetics acquires a priority role. In particular, IL-10 signaling pathway defects are associated with the development of early-onset IBD [35]. In contrast, IL23R allele variants have shown a protective role. In fact, T helper 17 lymphocytes from IBD patients (carriers of protective IL23R variant) show a decreased production in IL-17A in response to IL-23 stimulation [36,37]. In 20–30% of cases, IBDs are diagnosed in childhood or in young adulthood with male predominance [38]. The incidence of the disease is increasing in industrialized countries, suggesting that environmental and dietary factors play a key role [39,40]. In children, a positive family history of IBD remains an important risk factor for the development of IBD [41].
The most common symptoms and signs are diarrhea, weight loss, and abdominal pain. In UC, rectal bleeding is present in 83% of pediatric patients [42,43]. Fecal calprotectin, intestinal ultrasound, and magnetic resonance enterography may help with diagnosis, but esophagogastroduodenoscopy and colonoscopy remain the gold standard for diagnosis and classification. Extra-intestinal manifestations (EIM) can affect musculoskeletal (arthritis, osteopenia), dermatologic (pyoderma granulosum, erythema nodosum), hepatobiliary (pancreatitis, primary sclerosing cholangitis), renal (uveitis, episcleritis, iritis), and hematologic (anemia, deep venous thromboembolism) systems. Some EIM go hand in hand with intestinal inflammation, while others are independent (i.e., pyoderma gangrenosum) [33]. Joint involvement represents the most common EIM in IBD; commonly, it occurs within the first year after the onset of IBD symptoms. However, arthritis might be the presenting symptom of IBD in up to 4% of pediatric IBD cases [44]. The pattern of joint involvement might be heterogeneous: asymmetrical polyarticular or oligoarticular arthritis, arthralgia, enthesitis, and sacroiliitis [44]. During the disease course of pediatric IBD, sacroiliitis might be underrecognized due to the subtle symptoms, and can progress despite the IBD treatments. MR enterography (MRE) is used to assess IBD intestinal disease activity and might help to detect the underlining inflammation of sacroiliac joints. Indeed, a reevaluation of MRE in a cohort of children with IBD showed that, using the ASAS (Assessment of SpondyloArthritis international Society) criteria for signs of sacroiliitis, 15% of patients have mild sacroiliitis at MRE despite not complaining of any musculoskeletal symptoms [45]. The link between IBD and joint/bone inflammation might rely on the alteration of IL-23 and/or IL-17 axis, dysbiosis, and subclinical gut barrier dysfunction as well as genetic factors such as the HLA B27 positivity and NOD2 variants [46,47].

1.3. Association between CNO/CRMO and IBD

Since the first descriptions, the association with other inflammatory disorders such as inflammatory bowel disease (IBD), psoriasis, and arthritis has been reported [26,48]. In particular, the relationship between bone and intestinal inflammation is still poorly understood. On the other hand, the prevalence of musculoskeletal involvement in IBD is not negligible (up to 46%) [49], but the impact of CNO is unknown. In recent years, there has been a growing interest in the role of the gut microbiome in CNO. Lukens et al. demonstrated that a high-fat diet reduced Prevotella levels and pro-IL-1-beta expression in distant neutrophils in osteomyelitis-prone cmo mice [50]. In another study, an alteration in oral microbiome in CNO/CRMO patients in response to NSAID treatment was described. Another study described an alteration in the oral microbiome in CNO/CRMO patients responding to NSAID treatment [51]. A recent study has also highlighted compositional differences in fecal and oral microbiota between healthy controls and CRMO patients, drawing new attention to the potential role of dysbiosis in the pathology of CRMO [52].
This review aims to describe all the cases reported in the literature concerning the association between CNO and IBD and to compare them with data from our single-center cohort of patients affected by CNO but without a diagnosis of IBD. The comparison was assessed to comprehend if there are clinical or demographic differences between CNO alone or in association with IBD.

2. Materials and Methods

We conducted a literature review of published cases of CNO associated with IBD. Only articles published in peer-reviewed journals were included. Eligible articles were identified through a Medline search in the PubMed database until December 2022. No age limits or language restrictions were applied. To identify relevant reports, we used “Chronic nonbacterial osteomyelitis” OR “chronic recurrent multifocal osteomyelitis“ AND “inflammatory bowel diseases” OR “Crohn’s disease” OR “Ulcerative colitis” as search terms. Selected articles were manually screened by reading the titles and abstracts, and additional articles referenced by the above studies were reviewed to determine eligibility. We extrapolated individual patients’ data to perform a detailed analysis, creating a customized database. S.C. and S.G. reviewed the completed database to verify possible abstracting mistakes and/or case overlaps. Information not clearly stated in the text was labeled as unavailable. We retrospectively reviewed medical records of patients with CNO referred to G. Pini Hospital, and we compared demographic and clinical features from the literature-review-based cohort with our single-center cohort of patients affected by CNO. Descriptive statistics were used to summarize data. Categorical variables were expressed as percentages. The normality of variable distribution was tested by applying the Shapiro–Wilk test. Continuous variables with non-parametric distribution were expressed as median values (interquartile range, IQR). Associations between categorical predictors and outcomes were evaluated by Chi-square or Fisher’s exact test, as appropriate. p-values ≤ 0.05 were considered statistically significant. Analyses were performed with R commander.

3. Results

3.1. Literature-Review-Based Cohort

We identified 32 articles, 4 of which were excluded since they lacked essential data or the article was unavailable. The remaining 28 were considered eligible for the study [11,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75]. Fifty-seven patients with a defined diagnosis of CNO and associated IBD were described (female 26/47; 55%) through a literature review of published cases. The median age of onset of the disease (IBD or CNO) was 11 years (IQR 4.5); in particular, eight patients were adults at onset, while in the remaining patients, the condition had started before the age of 18. Among the patients, 35/42 (83%) had a polyostotic disease, while 7/42 (17%) had a mono-focal disease with a predominance of sternoclavicular involvement (3/7; 43%). The most frequent bone symptom was wrist pain (24%), followed by nonspecific pain in the lower extremities (19%). Constitutional symptoms were present in 21% of patients at the onset of the disease (n = 5 with a first diagnosis of CNO; n = 1 first diagnosis of IBD; n = 3 simultaneous diagnosis). Clinical features of the retrieved cases are summarized in Table 1.
The most commonly associated conditions were psoriasis (n = 5; 9%), sclerosing cholangitis (n = 2; 4%), and erythema nodosum (n = 2; 4%), while the other three patients suffered from Takayasu vasculitis, pyoderma gangrenosum, and Ehlers–Danlos syndrome. In 32/53 patients (60%), a histological diagnosis of CD was made, while 18 (34%) patients were classified as UC. In three (6%) cases, the bowel inflammation did not meet the histological criteria for the diagnosis of either condition, therefore, they were identified as u-IBD. The most frequent gastrointestinal symptoms at the onset of IBD were diarrhea (17/40; 43%), followed by hematochezia or blood in stools (12/40; 30%). In 28% (11/40) of patients, the only complained symptom was unspecific abdominal pain.
In 27 cases out of 46 patients (59%) with available data, the diagnosis of CNO preceded the diagnosis of IBD, and the median time between the two events was 24 months (IQR 40). Contrariwise, in 11 patients (24%), IBD anticipated bone symptoms with a median time between the two diagnoses of 24 months (IQR 40.3). The two conditions were diagnosed simultaneously in only eight patients (17%). We divided the patients into two groups: i. patients firstly diagnosed with CNO (CNO-first) and ii. patients firstly diagnosed with IBD (IBD-first). No statistically significant differences in CD/UC (p-value = 0.425), constitutional symptoms (p = 0.625), or sex prevalence (p-value = 0.709) were found between the two groups.
In contrast, the use of biological disease-modifying antirheumatic drugs (bDMARDs) differed between the two groups. In the CNO-first group, 1 patient out of 27 (4%) was treated with etanercept, and the remaining received a TNFα inhibitor (TNFα-i) only after the diagnosis of IBD, while in the IBD-first group, 5 patients out of 11 (45%) were under TNFα-i treatment when bone symptoms appeared (p-value = 0.004; [95% CI 1.7–1054.4]). Notably, in these patients, CNO had developed despite the previous use of TNFα-i (infliximab n = 4, adalimumab n = 1) for IBD treatment with a median time between the two conditions of 36 months (IQR 36).
In one patient (Group IBD-first), increasing the dosage of infliximab led to an improvement in bone symptoms. One patient switched from infliximab to ustekinumab, an anti-IL12/23 monoclonal antibody, and the other three patients experienced an improvement in CNO while remaining on the same anti-TNFα therapy.
In the CNO-first group, the different cumulative treatments used before and after IBD diagnosis are summarized in Table 2.
No further analysis on possible predictors of developing IBD or CNO, according to the first diagnosis, was undertaken, given the low numbers and the insufficiency of the extrapolated data.

3.2. Comparing Literature Data with the Italian Cohort

Twenty-three patients were included in the Italian cohort. The median age at the onset of CNO was 10 years (IQR 1.5), and the median follow-up time was 90 months (IQR 86). None of the patients in our cohort developed gastrointestinal symptoms or IBD over time. Every patient was screened with fecal calprotectin at the beginning and after one year from the diagnosis, but none had a positive test. The presenting clinical manifestations were bone pain (99%), with swelling of the affected bone in 22%, and constitutional signs, including fever (17%). Nineteen patients (83%) had a polyostotic disease, while four remained monostotic (50% with sternoclavicular involvement). Clinical and demographic features of the two cohorts are compared in Table 3.

4. Discussion

The association between CNO and IBD was described for the first time by Kahn et al. [76] in a case series. Afterward, an increasing number of cases reporting this association was published. Although most articles concern the pediatric population, in eight reported cases the first symptoms began after 18 years of age. Although the etiology of CNO is uncertain, the strong association with other inflammatory disorders might suggest a common pathophysiology. Some interesting hypotheses have been proposed. As is the case in the pathogenesis of spondyloarthritis (SpA), it was assumed that, also in CNO patients, an impaired intestinal barrier and a consequent inflammation might release cytokines, which can mediate the extraintestinal manifestation of IBD, particularly bone inflammation. In adults affected by spondylarthritis, a subclinical gut inflammation documented by ileocolonscopy was found in around 60% of patients [77,78,79,80]. Similar results were found in patients with juvenile SpA (jSpA) [81]. In patients diagnosed with enthesitis-related arthritis (ERA), calprotectin levels were influenced by bone disease status; indeed, patients with an active disease had higher levels of fecal calprotectin compared with those with a quiescent disease [82]. Another study found an increased incidence of IBD in jSpA patients compared to the healthy population [83,84,85]. These findings suggest a potential role of dysbiosis in the pathogenesis of both diseases: an imbalance in the microbiota may lead to an increase in gut wall permeability and a defective defense mechanism permitting antigens to enter the circulation and cause inflammation elsewhere [86]. Moreover, in adult SpA, gut inflammation correlates with both disease activity and progression [79,87]. Regarding genetic factors, the best-known susceptibility genes for IBD (i.e., CARD15/NOD2 gene) were tested in a small cohort of patients with CNO; however, no association was found [63].
Fifty-seven cases of patients diagnosed with both CNO and IBD have been reported in the literature. In most of the cases (59%), bone pain and CNO diagnosis preceded gastrointestinal symptoms. However, the latency between the first and second disease was the same between CNO-first and IBD-first groups (median time of 2 years). The majority of the patients were diagnosed with CD rather than with UC (60% vs. 34%).
In the literature-review-based cohort, the most common associated disease was psoriasis, and, as occurs for IBD, primary sclerosing cholangitis was the most common hepatobiliary complication [88,89].
We found a higher incidence of constitutional signs and symptoms in our literature-review-based cohort of CNO-IBD patients compared to CNO patients in the literature (21% vs. 5%) [9,30], but no significant difference when compared with our Italian cohort (21% vs. 17%; p-value = 0.758). Continuing the comparison, it seems that CNO-IBD patients had a lower incidence of rachis involvement compared to CNO patients from the Italian cohort (0% vs. 26%; p-value = 0.001).
Another interesting observation can be made regarding the use of bDMARDs when comparing patients with a first diagnosis of CNO and patients with a first diagnosis of IBD. In the first group, only one patient was treated with bDMARDs (etanercept) before the onset of gastrointestinal symptoms, while in the second group, five patients were under TNFα-i treatment when bone symptoms appeared. In this scenario, it seems that therapy with TNFα-i does not prevent the development of bone disease. Nevertheless, the efficacy of TNFα-i y in the treatment of NSAIDs refractory CNO is well known [90], and in some patients in the literature-review-based cohort, dosage adjustment led to bone disease remission.
The limitations of the present manuscript include the review analysis and the subsequent retrospective design. The time period of more than 20 years over which the published cases were reported may represent an undeniable bias. Furthermore, data from the literature might be incomplete and lack longitudinal details; therefore, a careful interpretation of each datum is needed. Conversely, our cohort represented a uniform sample; however its retrospective nature and the low number forbid any generalizable results. Nevertheless, this is the first complete literature review concerning the association between CNO and IBD. We not only reported published cases of this association, but we also compared this literature-review-based cohort with our cohort of CNO patients without IBD to find any possible difference.

5. Conclusions

Pediatric rheumatologists and gastroenterologists should be aware of the possibility of the association between the two diseases, especially in the presence of constitutional symptoms despite the ongoing treatment. The link between autoinflammatory bone disease and intestinal inflammation should be further investigated since it might offer insights into bone inflammation and new therapeutic options. We aim to increase the awareness of this association and its related characteristics in order to help clinicians in the early diagnosis and proper treatment.

Author Contributions

Conceptualization, S.C., S.G. and A.M.; methodology, S.C. and A.M.; formal analysis, S.C.; data curation, M.P., M.R.P. and A.A.; writing—original draft preparation S.C. and S.G.; writing—review and editing, M.G., C.B.C., R.C. and A.M.; supervision, M.G., C.B.C., R.C. and A.M. All authors have read and agreed to the published version of the manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The authors confirm that the data supporting the findings of this study are available within the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mahady, S.; Ladani, A. Clinical and Diagnostic Considerations for Atypical, Adult Onset Presentation of Chronic Recurrent Multifocal Osteomyelitis (CRMO). Case Rep. Rheumatol. 2019, 2019, 8206892. [Google Scholar] [CrossRef] [PubMed]
  2. Hofmann, S.R.; Kapplusch, F.; Girschick, H.J.; Morbach, H.; Pablik, J.; Ferguson, P.J.; Hedrich, C.M. Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Curr. Osteoporos. Rep. 2017, 15, 542–554. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Hofmann, S.R.; Kubasch, A.S.; Ioannidis, C.; Rösen-Wolff, A.; Girschick, H.J.; Morbach, H.; Hedrich, C.M. Altered Expression of IL-10 Family Cytokines in Monocytes from CRMO Patients Result in Enhanced IL-1β Expression and Release. Clin. Immunol. 2015, 161, 300–307. [Google Scholar] [CrossRef]
  4. Brandt, D.; Sohr, E.; Pablik, J.; Schnabel, A.; Kapplusch, F.; Mäbert, K.; Girschick, J.H.; Morbach, H.; Thielemann, F.; Hofmann, S.R.; et al. CD14+ Monocytes Contribute to Inflammation in Chronic Nonbacterial Osteomyelitis (CNO) through Increased NLRP3 Inflammasome Expression. Clin. Immunol. 2018, 196, 77–84. [Google Scholar] [CrossRef]
  5. Morbach, H.; Hedrich, C.M.; Beer, M.; Girschick, H.J. Autoinflammatory Bone Disorders. Clin. Immunol. 2013, 147, 185–196. [Google Scholar] [CrossRef] [PubMed]
  6. Nakashima, T.; Takayanagi, H. Osteoimmunology: Crosstalk between the Immune and Bone Systems. J. Clin. Immunol. 2009, 29, 555–567. [Google Scholar] [CrossRef]
  7. Scianaro, R.; Insalaco, A.; Bracci Laudiero, L.; De Vito, R.; Pezzullo, M.; Teti, A.; De Benedetti, F.; Prencipe, G. Deregulation of the IL-1β Axis in Chronic Recurrent Multifocal Osteomyelitis. Pediatr. Rheumatol. 2014, 12, 30. [Google Scholar] [CrossRef] [Green Version]
  8. Golla, A.; Jansson, A.; Ramser, J.; Hellebrand, H.; Zahn, R.; Meitinger, T.; Belohradsky, B.H.; Meindl, A. Chronic Recurrent Multifocal Osteomyelitis (CRMO): Evidence for a Susceptibility Gene Located on Chromosome 18q21.3–18q22. Eur. J. Hum. Genet. 2002, 10, 217–221. [Google Scholar] [CrossRef] [Green Version]
  9. Jansson, A.F.; Grote, V. ESPED Study Group Nonbacterial Osteitis in Children: Data of a German Incidence Surveillance Study. Acta Paediatr. 2011, 100, 1150–1157. [Google Scholar] [CrossRef]
  10. Schnabel, A.; Range, U.; Hahn, G.; Siepmann, T.; Berner, R.; Hedrich, C.M. Unexpectedly High Incidences of Chronic Non-Bacterial as Compared to Bacterial Osteomyelitis in Children. Rheumatol. Int. 2016, 36, 1737–1745. [Google Scholar] [CrossRef]
  11. Jansson, A.; Renner, E.D.; Ramser, J.; Mayer, A.; Haban, M.; Meindl, A.; Grote, V.; Diebold, J.; Schneider, K.; Belohradsky, B.H. Classification of Non-Bacterial Osteitis: Retrospective Study of Clinical, Immunological and Genetic Aspects in 89 Patients. Rheumatology 2007, 46, 154–160. [Google Scholar] [CrossRef] [Green Version]
  12. Ben Becher, S.; Essaddam, H.; Nahali, N.; Ben Hamadi, F.; Mouelhi, M.H.; Hammou, A.; Hadj Romdhane, L.; Ben Cheikh, M.; Boudhina, T.; Dargouth, M. [Recurrent multifocal periostosis in children. Report of a familial form]. Ann. Pediatr. (Paris) 1991, 38, 345–349. [Google Scholar] [PubMed]
  13. Zhao, D.Y.; McCann, L.; Hahn, G.; Hedrich, C.M. Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO). J. Transl. Autoimmun. 2021, 4, 100095. [Google Scholar] [CrossRef] [PubMed]
  14. Hoffman, H.M.; Broderick, L. The Role of the Inflammasome in Patients with Autoinflammatory Diseases. J. Allergy Clin. Immunol. 2016, 138, 3–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Harapas, C.R.; Steiner, A.; Davidson, S.; Masters, S.L. An Update on Autoinflammatory Diseases: Inflammasomopathies. Curr. Rheumatol. Rep. 2018, 20, 40. [Google Scholar] [CrossRef] [PubMed]
  16. Majeed, H.A.; Kalaawi, M.; Mohanty, D.; Teebi, A.S.; Tunjekar, M.F.; al-Gharbawy, F.; Majeed, S.A.; al-Gazzar, A.H. Congenital Dyserythropoietic Anemia and Chronic Recurrent Multifocal Osteomyelitis in Three Related Children and the Association with Sweet Syndrome in Two Siblings. J. Pediatr. 1989, 115, 730–734. [Google Scholar] [CrossRef]
  17. Ferguson, P.J.; El-Shanti, H. Majeed Syndrome: A Review of the Clinical, Genetic and Immunologic Features. Biomolecules 2021, 11, 367. [Google Scholar] [CrossRef]
  18. Aksentijevich, I.; Masters, S.L.; Ferguson, P.J.; Dancey, P.; Frenkel, J.; van Royen-Kerkhoff, A.; Laxer, R.; Tedgård, U.; Cowen, E.W.; Pham, T.-H.; et al. An Autoinflammatory Disease with Deficiency of the Interleukin-1—Receptor Antagonist. N. Engl. J. Med. 2009, 360, 2426–2437. [Google Scholar] [CrossRef] [Green Version]
  19. Reddy, S.; Jia, S.; Geoffrey, R.; Lorier, R.; Suchi, M.; Broeckel, U.; Hessner, M.J.; Verbsky, J. An Autoinflammatory Disease Due to Homozygous Deletion of the IL1RN Locus. N. Engl. J. Med. 2009, 360, 2438–2444. [Google Scholar] [CrossRef] [Green Version]
  20. Hospach, T.; Glowatzki, F.; Blankenburg, F.; Conzelmann, D.; Stirnkorb, C.; Müllerschön, C.S.; von den Driesch, P.; Köhler, L.M.; Rohlfs, M.; Klein, C.; et al. Scoping Review of Biological Treatment of Deficiency of Interleukin-36 Receptor Antagonist (DITRA) in Children and Adolescents. Pediatr. Rheumatol. 2019, 17, 37. [Google Scholar] [CrossRef] [Green Version]
  21. Mukai, T.; Fujita, S.; Morita, Y. Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2. Cells 2019, 8, 195. [Google Scholar] [CrossRef] [Green Version]
  22. Cox, A.J.; Darbro, B.W.; Laxer, R.M.; Velez, G.; Bing, X.; Finer, A.L.; Erives, A.; Mahajan, V.B.; Bassuk, A.G.; Ferguson, P.J. Recessive Coding and Regulatory Mutations in FBLIM1 Underlie the Pathogenesis of Chronic Recurrent Multifocal Osteomyelitis (CRMO). PLoS ONE 2017, 12, e0169687. [Google Scholar] [CrossRef] [Green Version]
  23. Xiao, G.; Cheng, H.; Cao, H.; Chen, K.; Tu, Y.; Yu, S.; Jiao, H.; Yang, S.; Im, H.-J.; Chen, D.; et al. Critical Role of Filamin-Binding LIM Protein 1 (FBLP-1)/Migfilin in Regulation of Bone Remodeling. J. Biol. Chem. 2012, 287, 21450–21460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. d’Adamo, A.P.; Bianco, A.M.; Ferrara, G.; La Bianca, M.; Insalaco, A.; Tommasini, A.; Pardeo, M.; Cattalini, M.; La Torre, F.; Finetti, M.; et al. High Prevalence of Rare FBLIM1 Gene Variants in an Italian Cohort of Patients with Chronic Non-Bacterial Osteomyelitis (CNO). Pediatr. Rheumatol. 2020, 18, 55. [Google Scholar] [CrossRef] [PubMed]
  25. Roderick, M.R.; Shah, R.; Rogers, V.; Finn, A.; Ramanan, A.V. Chronic Recurrent Multifocal Osteomyelitis (CRMO)—Advancing the Diagnosis. Pediatr. Rheumatol. 2016, 14, 47. [Google Scholar] [CrossRef] [Green Version]
  26. Wipff, J.; Costantino, F.; Lemelle, I.; Pajot, C.; Duquesne, A.; Lorrot, M.; Faye, A.; Bader-Meunier, B.; Brochard, K.; Despert, V.; et al. A Large National Cohort of French Patients with Chronic Recurrent Multifocal Osteitis. Arthritis Rheumatol. 2015, 67, 1128–1137. [Google Scholar] [CrossRef]
  27. Beck, C.; Morbach, H.; Beer, M.; Stenzel, M.; Tappe, D.; Gattenlöhner, S.; Hofmann, U.; Raab, P.; Girschick, H.J. Chronic Nonbacterial Osteomyelitis in Childhood: Prospective Follow-up during the First Year of Anti-Inflammatory Treatment. Arthritis Res. Ther. 2010, 12, R74. [Google Scholar] [CrossRef] [Green Version]
  28. Aden, S.; Wong, S.; Yang, C.; Bui, T.; Higa, T.; Scheck, J.; Iyer, R.S.; Egbert, M.; Lindberg, A.; Zhao, Y. Increasing Cases of Chronic Nonbacterial Osteomyelitis in Children: A Series of 215 Cases From a Single Tertiary Referral Center. J. Rheumatol. 2022, 49, 929–934. [Google Scholar] [CrossRef]
  29. Menashe, S.J.; Aboughalia, H.; Zhao, Y.; Ngo, A.-V.; Otjen, J.P.; Thapa, M.M.; Iyer, R.S. The Many Faces of Pediatric Chronic Recurrent Multifocal Osteomyelitis (CRMO): A Practical Location- and Case-Based Approach to Differentiate CRMO From Its Mimics. J. Magn. Reson. Imaging 2021, 54, 391–400. [Google Scholar] [CrossRef]
  30. Jansson, A.F.; Müller, T.H.; Gliera, L.; Ankerst, D.P.; Wintergerst, U.; Belohradsky, B.H.; Jansson, V. Clinical Score for Nonbacterial Osteitis in Children and Adults. Arthritis Rheum. 2009, 60, 1152–1159. [Google Scholar] [CrossRef]
  31. Fritz, J.; Tzaribatchev, N.; Claussen, C.D.; Carrino, J.A.; Horger, M.S. Chronic Recurrent Multifocal Osteomyelitis: Comparison of Whole-Body MR Imaging with Radiography and Correlation with Clinical and Laboratory Data. Radiology 2009, 252, 842–851. [Google Scholar] [CrossRef] [PubMed]
  32. Hedrich, C.M.; Hofmann, S.R.; Pablik, J.; Morbach, H.; Girschick, H.J. Autoinflammatory Bone Disorders with Special Focus on Chronic Recurrent Multifocal Osteomyelitis (CRMO). Pediatr. Rheumatol. 2013, 11, 47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Rubalcava, N.S.; Gadepalli, S.K. Inflammatory Bowel Disease in Children and Adolescents. Adv. Pediatr. 2021, 68, 121–142. [Google Scholar] [CrossRef] [PubMed]
  34. Khor, B.; Gardet, A.; Xavier, R.J. Genetics and Pathogenesis of Inflammatory Bowel Disease. Nature 2011, 474, 307–317. [Google Scholar] [CrossRef] [Green Version]
  35. Ouahed, J.; Spencer, E.; Kotlarz, D.; Shouval, D.S.; Kowalik, M.; Peng, K.; Field, M.; Grushkin-Lerner, L.; Pai, S.-Y.; Bousvaros, A.; et al. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm. Bowel Dis. 2020, 26, 820–842. [Google Scholar] [CrossRef]
  36. Di Meglio, P.; Di Cesare, A.; Laggner, U.; Chu, C.-C.; Napolitano, L.; Villanova, F.; Tosi, I.; Capon, F.; Trembath, R.C.; Peris, K.; et al. The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans. PLoS ONE 2011, 6, e17160. [Google Scholar] [CrossRef] [Green Version]
  37. Momozawa, Y.; Mni, M.; Nakamura, K.; Coppieters, W.; Almer, S.; Amininejad, L.; Cleynen, I.; Colombel, J.-F.; de Rijk, P.; Dewit, O.; et al. Resequencing of Positional Candidates Identifies Low Frequency IL23R Coding Variants Protecting against Inflammatory Bowel Disease. Nat. Genet. 2011, 43, 43–47. [Google Scholar] [CrossRef]
  38. Kaplan, G.G. The Global Burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 720–727. [Google Scholar] [CrossRef]
  39. Molodecky, N.A.; Soon, I.S.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Barkema, H.W.; et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases with Time, Based on Systematic Review. Gastroenterology 2012, 142, 46–54.e42. [Google Scholar] [CrossRef] [Green Version]
  40. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies. Lancet 2017, 390, 2769–2778. [Google Scholar] [CrossRef]
  41. Childers, R.E.; Eluri, S.; Vazquez, C.; Weise, R.M.; Bayless, T.M.; Hutfless, S. Family History of Inflammatory Bowel Disease among Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis. J. Crohns Colitis 2014, 8, 1480–1497. [Google Scholar] [CrossRef] [PubMed]
  42. Benchimol, E.I.; Bernstein, C.N.; Bitton, A.; Carroll, M.W.; Singh, H.; Otley, A.R.; Vutcovici, M.; El-Matary, W.; Nguyen, G.C.; Griffiths, A.M.; et al. Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. Am. J. Gastroenterol. 2017, 112, 1120–1134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Kugathasan, S.; Judd, R.H.; Hoffmann, R.G.; Heikenen, J.; Telega, G.; Khan, F.; Weisdorf-Schindele, S.; San Pablo, W.; Perrault, J.; Park, R.; et al. Epidemiologic and Clinical Characteristics of Children with Newly Diagnosed Inflammatory Bowel Disease in Wisconsin: A Statewide Population-Based Study. J. Pediatr. 2003, 143, 525–531. [Google Scholar] [CrossRef] [PubMed]
  44. Levy, R.; Amarilyo, G.; Tal, R.; Amir, J.; Assa, A.; Rinawi, F.; Harel, L. Musculoskeletal Manifestations as Presenting Symptoms of Inflammatory Bowel Disease in Children and Adolescents. J. Pediatr. 2019, 209, 233–235. [Google Scholar] [CrossRef] [PubMed]
  45. Giani, T.; Bernardini, A.; Basile, M.; Di Maurizo, M.; Perrone, A.; Renzo, S.; Filistrucchi, V.; Cimaz, R.; Lionetti, P. Usefulness of Magnetic Resonance Enterography in Detecting Signs of Sacroiliitis in Young Patients with Inflammatory Bowel Disease. Pediatr. Rheumatol. 2020, 18, 42. [Google Scholar] [CrossRef] [PubMed]
  46. Ricciuto, A.; Sherman, P.M.; Laxer, R.M. Gut Microbiota in Chronic Inflammatory Disorders: A Focus on Pediatric Inflammatory Bowel Diseases and Juvenile Idiopathic Arthritis. Clin. Immunol. 2020, 215, 108415. [Google Scholar] [CrossRef]
  47. Sharif, K.; Bridgewood, C.; Dubash, S.; McGonagle, D. Intestinal and Enthesis Innate Immunity in Early Axial Spondyloarthropathy. Rheumatology 2020, 59, iv67–iv78. [Google Scholar] [CrossRef]
  48. Girschick, H.; Finetti, M.; Orlando, F.; Schalm, S.; Insalaco, A.; Ganser, G.; Nielsen, S.; Herlin, T.; Koné-Paut, I.; Martino, S.; et al. The Multifaceted Presentation of Chronic Recurrent Multifocal Osteomyelitis: A Series of 486 Cases from the Eurofever International Registry. Rheumatology 2018, 57, 1504. [Google Scholar] [CrossRef] [Green Version]
  49. Salvarani, C.; Vlachonikolis, I.G.; van der Heijde, D.M.; Fornaciari, G.; Macchioni, P.; Beltrami, M.; Olivieri, I.; Di Gennaro, F.; Politi, P.; Stockbrügger, R.W.; et al. Musculoskeletal Manifestations in a Population-Based Cohort of Inflammatory Bowel Disease Patients. Scand. J. Gastroenterol. 2001, 36, 1307–1313. [Google Scholar] [CrossRef]
  50. Lukens, J.R.; Gurung, P.; Vogel, P.; Johnson, G.R.; Carter, R.A.; McGoldrick, D.J.; Bandi, S.R.; Calabrese, C.R.; Vande Walle, L.; Lamkanfi, M.; et al. Dietary Modulation of the Microbiome Affects Autoinflammatory Disease. Nature 2014, 516, 246–249. [Google Scholar] [CrossRef] [Green Version]
  51. Zeus, M.; Janssen, S.; Laws, H.-J.; Fischer, U.; Borkhardt, A.; Oommen, P.T. Results from a Pilot Study on the Oral Microbiome in Children and Adolescents with Chronic Nonbacterial Osteomyelitis. Z. Rheumatol. 2021, 1–10. [Google Scholar] [CrossRef] [PubMed]
  52. Rausch, P.; Hartmann, M.; Baines, J.F.; von Bismarck, P. Analysis of the Fecal and Oral Microbiota in Chronic Recurrent Multifocal Osteomyelitis. Arthritis Res. Ther. 2022, 24, 54. [Google Scholar] [CrossRef] [PubMed]
  53. Bazrafshan, A.; Zanjani, K.S. Chronic Recurrent Multifocal Osteomyelitis Associated with Ulcerative Colitis: A Case Report. J. Pediatr. Surg. 2000, 35, 1520–1522. [Google Scholar] [CrossRef] [PubMed]
  54. Carpenter, E.; Jackson, M.A.; Friesen, C.A.; Scarbrough, M.; Roberts, C.C. Crohn’s-Associated Chronic Recurrent Multifocal Osteomyelitis Responsive to Infliximab. J. Pediatr. 2004, 144, 541–544. [Google Scholar] [CrossRef]
  55. Audu, G.K.; Nikaki, K.; Crespi, D.; Spray, C.; Epstein, J. Chronic Recurrent Multifocal Osteomyelitis and Inflammatory Bowel Disease. J. Pediatr. Gastroenterol. Nutr. 2015, 60, 586–591. [Google Scholar] [CrossRef] [PubMed]
  56. Kim, Y.S.; Lee, J.; Kim, H.-S. Sternocostal Involvement in Chronic Recurrent Multifocal Osteomyelitis Associated with Ulcerative Colitis. Rheumatol. Int. 2013, 33, 2889–2892. [Google Scholar] [CrossRef]
  57. Schilling, F.; Märker-Hermann, E. [Chronic recurrent multifocal osteomyelitis in association with chronic inflammatory bowel disease: Entheropathic CRMO]. Z. Rheumatol. 2003, 62, 527–538. [Google Scholar] [CrossRef]
  58. Bousvaros, A.; Marcon, M.; Treem, W.; Waters, P.; Issenman, R.; Couper, R.; Burnell, R.; Rosenberg, A.; Rabinovich, E.; Kirschner, B.S. Chronic Recurrent Multifocal Osteomyelitis Associated with Chronic Inflammatory Bowel Disease in Children. Dig. Dis. Sci. 1999, 44, 2500–2507. [Google Scholar] [CrossRef]
  59. Ahmed, A.B.M.; Alsaleem, B.M.R. Unusual Manifestation of Ulcerative Colitis. Case Rep. Pediatr. 2019, 2019, 5163213. [Google Scholar] [CrossRef]
  60. Bognar, M.; Blake, W.; Agudelo, C. Chronic Recurrent Multifocal Osteomyelitis Associated with Crohn’s Disease. Am. J. Med. Sci. 1998, 315, 133–135. [Google Scholar] [CrossRef]
  61. Lorenze, A.; Meadows, L.; Kehinde, T.; Menchini, C.B. A Severe Presentation of Chronic Non-Infectious Osteomyelitis Associated with Ulcerative Colitis: A Case Report. BMC Pediatr. 2020, 20, 304. [Google Scholar] [CrossRef] [PubMed]
  62. Ramraj, R.; Chun, C.; Marcovici, P. Chronic Recurrent Multifocal Osteomyelitis in Crohn Disease: Complete Resolution With Anti-TNFα Therapy. J. Pediatr. Gastroenterol. Nutr. 2018, 67, e57. [Google Scholar] [CrossRef] [PubMed]
  63. Morbach, H.; Dick, A.; Beck, C.; Stenzel, M.; Müller-Hermelink, H.K.; Raab, P.; Girschick, H.J. Association of Chronic Non-Bacterial Osteomyelitis with Crohn’s Disease but Not with CARD15 Gene Variants. Rheumatol. Int. 2010, 30, 617–621. [Google Scholar] [CrossRef] [PubMed]
  64. De Guerra, V.C.; Hashmi, H.; Kramer, B.; Balluz, R.; Son, M.B.; Stein, D.; Lieberman, A.; Zahra, M.; Abdul-Aziz, R. A Case Report of Takayasu’s Arteritis and Ulcerative Colitis in a Pediatric Patient with Chronic Recurrent Multifocal Osteomyelitis Successfully Treated with Infliximab: Diagnostic Clues in Disease Associations and Immune Dysregulation. Case Rep. Rheumatol. 2019, 2019, 8157969. [Google Scholar] [CrossRef] [Green Version]
  65. van Ommen, C.; Dehoorne, J.; De Baets, F.; Vande Velde, S.; Van Winckel, M.; Van Biervliet, S. A Case of Chronic Recurrent Multifocal Osteomyelitis Associated with Crohn’s Disease. Acta Gastro-Enterol. Belg. 2015, 78, 240–243. [Google Scholar]
  66. von Kalle, T.; Heim, N.; Hospach, T.; Langendörfer, M.; Winkler, P.; Stuber, T. Typical Patterns of Bone Involvement in Whole-Body MRI of Patients with Chronic Recurrent Multifocal Osteomyelitis (CRMO). ROFO. Fortschr. Geb. Rontgenstr. Nuklearmed. 2013, 185, 655–661. [Google Scholar] [CrossRef] [Green Version]
  67. Girschick, H.J.; Zimmer, C.; Klaus, G.; Darge, K.; Dick, A.; Morbach, H. Chronic Recurrent Multifocal Osteomyelitis: What Is It and How Should It Be Treated? Nat. Clin. Pract. Rheumatol. 2007, 3, 733–738. [Google Scholar] [CrossRef]
  68. Bret, J.; Lemaire, O.; Prat, C.; Zabraniecki, L.; Fournie, B. Aseptic Osteomyelitis Responding to TNFalpha Antagonist Therapy in a Patient with Crohn’s Disease. Joint Bone Spine 2008, 75, 489–491. [Google Scholar] [CrossRef]
  69. Manners, P.; Robbins, P. Chronic Recurrent Multifocal Osteomyelitis with Crohn’s Disease Exacerbation and Vasculitis after Granulocyte Colony-Stimulating Factor Therapy. JCR J. Clin. Rheumatol. 2000, 6, 283–290. [Google Scholar] [CrossRef]
  70. Altepeter, T.; Adeyemi, A. P-167 YI Multiple Bony Complications of Crohn’s Disease. Inflamm. Bowel Dis. 2013, 19, S92–S93. [Google Scholar] [CrossRef]
  71. Fujisaki, T.; Matsuishi, T.; Kamizono, J.; Amamoto, M.; Mizuochi, T. Crohn’s Disease and Chronic Recurrent Multifocal Osteomyelitis in a Japanese Boy. Pediatr. Int. 2021, 63, 115–117. [Google Scholar] [CrossRef] [PubMed]
  72. Ng, H.Y.; Guttman, O.R.; Tucker, L.B. Chronic Recurrent Multifocal Osteomyelitis and Primary Sclerosing Cholangitis with Type 1 Autoimmune Hepatitis in a Child with Ulcerative Colitis: A Case Report. BMC Rheumatol. 2021, 5, 16. [Google Scholar] [CrossRef] [PubMed]
  73. Dushnicky, M.J.; Beattie, K.A.; Cellucci, T.; Heale, L.; Zachos, M.; Sherlock, M.; Batthish, M. Pediatric Patients with a Dual Diagnosis of Inflammatory Bowel Disease and Chronic Recurrent Multifocal Osteomyelitis. J. Pediatr. Gastroenterol. Nutr. 2021, 73, 626–629. [Google Scholar] [CrossRef] [PubMed]
  74. Mambelli, L.; Giovannelli, E.; Mainetti, M.; Marchetti, F. From Bone Pain to Abdominal Pain: When Chronic Recurrent Multifocal Osteomyelitis Is Associated with Ulcerative Colitis. Pediatr. Neonatol. 2022, 63, 557–558. [Google Scholar] [CrossRef]
  75. Kim, M.C.; Kim, K.O.; Kang, M.K.; Jang, B.I. Chronic Recurrent Multifocal Osteomyelitis of the Left Femur Associated with Ulcerative Colitis: A Case Report. J. Int. Med. Res. 2021, 49, 3000605211042996. [Google Scholar] [CrossRef]
  76. Kahn, M.F. Chronic Recurrent Multifocal Osteomyelitis. Association with Vertebra Plana. J. Bone Joint Surg. Am. 1990, 72, 305–306. [Google Scholar] [CrossRef]
  77. Mielants, H.; Veys, E.M.; De Vos, M.; Cuvelier, C.; Goemaere, S.; De Clercq, L.; Schatteman, L.; Elewaut, D. The Evolution of Spondyloarthropathies in Relation to Gut Histology. I. Clinical Aspects. J. Rheumatol. 1995, 22, 2266–2272. [Google Scholar]
  78. Mielants, H.; Veys, E.M.; Cuvelier, C.; De Vos, M.; Goemaere, S.; De Clercq, L.; Schatteman, L.; Elewaut, D. The Evolution of Spondyloarthropathies in Relation to Gut Histology. II. Histological Aspects. J. Rheumatol. 1995, 22, 2273–2278. [Google Scholar]
  79. Mielants, H.; Veys, E.M.; Cuvelier, C.; De Vos, M.; Goemaere, S.; De Clercq, L.; Schatteman, L.; Gyselbrecht, L.; Elewaut, D. The Evolution of Spondyloarthropathies in Relation to Gut Histology. III. Relation between Gut and Joint. J. Rheumatol. 1995, 22, 2279–2284. [Google Scholar]
  80. Mielants, H.; Veys, E.M.; Cuvelier, C.; de Vos, M. Ileocolonoscopic Findings in Seronegative Spondylarthropathies. Br. J. Rheumatol. 1988, 27 (Suppl. S2), 95–105. [Google Scholar] [CrossRef]
  81. Mielants, H.; Veys, E.M.; Cuvelier, C.; De Vos, M.; Goemaere, S.; Maertens, M.; Joos, R. Gut Inflammation in Children with Late Onset Pauciarticular Juvenile Chronic Arthritis and Evolution to Adult Spondyloarthropathy—A Prospective Study. J. Rheumatol. 1993, 20, 1567–1572. [Google Scholar]
  82. Lamot, L.; Miler, M.; Vukojević, R.; Vidović, M.; Lamot, M.; Trutin, I.; Gabaj, N.N.; Harjaček, M. The Increased Levels of Fecal Calprotectin in Children With Active Enthesitis Related Arthritis and MRI Signs of Sacroiliitis: The Results of a Single Center Cross-Sectional Exploratory Study in Juvenile Idiopathic Arthritis Patients. Front. Med. 2021, 8, 650619. [Google Scholar] [CrossRef] [PubMed]
  83. Zisman, D.; Gladman, D.D.; Stoll, M.L.; Strand, V.; Lavi, I.; Hsu, J.J.; Mellins, E.D.; The CARRA Legacy Registry Investigators. The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes. J. Rheumatol. 2017, 44, 342–351. [Google Scholar] [CrossRef]
  84. Van Straalen, J.W.; Krol, R.M.; Giancane, G.; Panaviene, V.; Ailioaie, L.M.; Doležalová, P.; Cattalini, M.; Susic, G.; Sztajnbok, F.R.; Maritsi, D.; et al. Increased Incidence of Inflammatory Bowel Disease on Etanercept in Juvenile Idiopathic Arthritis Regardless of Concomitant Methotrexate Use. Rheumatology 2022, 61, 2104–2112. [Google Scholar] [CrossRef] [PubMed]
  85. Pagnini, I.; Scavone, M.; Maccora, I.; Mastrolia, M.V.; Marrani, E.; Bertini, F.; Lamot, L.; Simonini, G. The Development of Extra-Articular Manifestations in Children With Enthesitis-Related Arthritis: Natural Course or Different Disease Entity? Front. Med. 2021, 8, 667305. [Google Scholar] [CrossRef] [PubMed]
  86. Spadoni, I.; Zagato, E.; Bertocchi, A.; Paolinelli, R.; Hot, E.; Di Sabatino, A.; Caprioli, F.; Bottiglieri, L.; Oldani, A.; Viale, G.; et al. A Gut-Vascular Barrier Controls the Systemic Dissemination of Bacteria. Science 2015, 350, 830–834. [Google Scholar] [CrossRef]
  87. Macaluso, F.; Guggino, G.; Rizzo, A.; Ferrante, A.; Ciccia, F. Histopathology of the Gut in Rheumatic Diseases. Reumatismo 2018, 70, 178–186. [Google Scholar] [CrossRef] [Green Version]
  88. Vavricka, S.R.; Schoepfer, A.; Scharl, M.; Lakatos, P.L.; Navarini, A.; Rogler, G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2015, 21, 1982–1992. [Google Scholar] [CrossRef] [Green Version]
  89. Wang, C.-R.; Tsai, H.-W. Autoimmune Liver Diseases in Systemic Rheumatic Diseases. World J. Gastroenterol. 2022, 28, 2527–2545. [Google Scholar] [CrossRef]
  90. Zhao, Y.; Wu, E.Y.; Oliver, M.S.; Cooper, A.M.; Basiaga, M.L.; Vora, S.S.; Lee, T.C.; Fox, E.; Amarilyo, G.; Stern, S.M.; et al. Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. Arthritis Care Res. 2018, 70, 1228–1237. [Google Scholar] [CrossRef]
Table
Table 1. Clinical and demographic characteristics of reviewed cases of CNO associated with IBD.
Table 1. Clinical and demographic characteristics of reviewed cases of CNO associated with IBD.
Literature-Review-Based Cohort, Positive Findings/Pts with Available Information (%)
Female sex26/47 (57)
Polyostotic disease35/42 (83)
Family history of autoimmune disease (1–2° degree)
Psoriasis3/56 (5)
IBD3/56 (5)
Constitutional symptoms at the onset9/42 (21)
Laboratory features the onset
ANA positivity3/17 (18)
ANCA positivity3/17 (18)
Low Hb levels14/17 (83)
High calprotectin levels10/12 (83)
High ESR/RCP38/41 (93)
IBD = inflammatory bowel disease; ANA = antinuclear antibodies; ANCA = anti-neutrophil cytoplasmic antibodies; Hb = hemoglobin; ESR = erythrocyte sedimentation rate; CRP = reactive c protein; Pts = patients.
Table
Table 2. Patient firstly diagnosed with CNO: treatment differences before and after IBD diagnosis.
Table 2. Patient firstly diagnosed with CNO: treatment differences before and after IBD diagnosis.
TreatmentsBefore IBD DiagnosisAfter IBD Diagnosisp-Value
NSAIDs1500.000
Steroids7120.237
Salicylates0130.000
MTX240.666
IVIG101
AZA060.021
Anti-TNFα 160.097
NSAIDs = non-steroidal anti-inflammatory drugs; MTX = methotrexate; IVIG = intravenous immunoglobulins; AZA = azathioprine; TNFα-i = tumor necrosis factor α inhibitors; IBD = inflammatory bowel diseases.
Table
Table 3. Demographical and clinical features of CNO in the Italian cohort vs. literature-review-based cohort.
Table 3. Demographical and clinical features of CNO in the Italian cohort vs. literature-review-based cohort.
Italian Cohort
Positive Findings/Pts with Available Information (%)		Literature-Review-Based Cohort
Positive Findings/Pts with Available Information (%)		p-Value
Female sex18/23 (78)26/47 (57)0.071
Age at onset, median (IQR)10 (1.5)11 (4.5)0.095
Comorbidity
Psoriasis 0/23 (0)5/56 (9)0.314
Erythema nodosum 0/23 (0)2/56 (4)1
Sclerosing colanghitis0/23 (0)2/56 (4)1
Hypothyroidism 2/23 (9)0/56 (0)0.082
Celiac disease1/23 (4)0/56 (0)0.291
Takayasu vasculitis0/23 (0)1/56 (2)1
Pyoderma gangrenosum1/231/56 (2)0.500
Polyostotic disease19/23 (83)35/42 (83)1
Constitutional symptoms at onset4/23 (17)9/42 (21)0.758
Bone pain at the onset
Knee2/23 (9)5/42 (12)1
Ankle 2/23 (9)10/42 (24)0.187
Foot1/23 (4)3/42 (7)1
Jaw0/23 (0)3/42 (7)0.546
Sternoclavear3/23 (13)6/42 (14)1
Pelvis and SI joints4/23 (17)5/42 (12)0.709
Tibia2/23 (9)2/42 (5)0.610
Not specific lower extremity pain3/23 (13)8/42 (19)0.733
Diffuse bone pain3/23 (13)3/42 (7)0.686
Rachis6/23 (26)0/42 (0)0.001
First line therapy in patients with CNO first presentation
NSAIDs only4/22 (18)13/20 (65)0.004
NSAIDs + csDMARDs4/22 (18)2/20 (10)0.665
Bisphosphonates only7/22 (32)1/20 (5)0.047
Bisphosphonates + csDMARDs6/22 (27)0/20 (0)0.021
Steroids0/22 (0)5/20 (25)0.018
NSAIDs = non-steroidal anti-inflammatory drugs; csDMARDs = conventional disease modifying antirheumatic drugs; CNO = chronic nonbacterial osteomyelitis.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Costi, S.; Germinario, S.; Pandolfi, M.; Pellico, M.R.; Amati, A.; Gattinara, M.; Chighizola, C.B.; Caporali, R.; Marino, A. Chronic Nonbacterial Osteomyelitis and Inflammatory Bowel Disease: A Literature Review-Based Cohort. Children 2023, 10, 502. https://doi.org/10.3390/children10030502

AMA Style

Costi S, Germinario S, Pandolfi M, Pellico MR, Amati A, Gattinara M, Chighizola CB, Caporali R, Marino A. Chronic Nonbacterial Osteomyelitis and Inflammatory Bowel Disease: A Literature Review-Based Cohort. Children. 2023; 10(3):502. https://doi.org/10.3390/children10030502

Chicago/Turabian Style

Costi, Stefania, Sabino Germinario, Marco Pandolfi, Maria Rosa Pellico, Andrea Amati, Maurizio Gattinara, Cecilia Beatrice Chighizola, Roberto Caporali, and Achille Marino. 2023. "Chronic Nonbacterial Osteomyelitis and Inflammatory Bowel Disease: A Literature Review-Based Cohort" Children 10, no. 3: 502. https://doi.org/10.3390/children10030502

APA Style

Costi, S., Germinario, S., Pandolfi, M., Pellico, M. R., Amati, A., Gattinara, M., Chighizola, C. B., Caporali, R., & Marino, A. (2023). Chronic Nonbacterial Osteomyelitis and Inflammatory Bowel Disease: A Literature Review-Based Cohort. Children, 10(3), 502. https://doi.org/10.3390/children10030502

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop